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Abstract
Encapsulating peritoneal sclerosis (EPS) is a life threatening complication of peritoneal dialysis (PD). Podoplanin is a
glycoprotein expressed by mesothelial cells, lymphatic endothelial cells, and myofibroblasts in peritoneal biopsies from
patients with EPS. To evaluate podoplanin as a marker of EPS we measured podoplanin mRNA and described the
morphological patterns of podoplanin-positive cells in EPS. Included were 20 peritoneal biopsies from patients with the
diagnosis of EPS (n = 5), patients on PD without signs of EPS (n = 5), and control patients (uremic patients not on PD, n = 5,
non-uremic patients n = 5). EPS patient biopsies revealed significantly elevated levels of podoplanin mRNA (p,0.05). In 24
peritoneal biopsies from patients with EPS, podoplanin and smooth muscle actin (SMA) were localized by
immunohistochemistry. Four patterns of podoplanin distribution were distinguishable. The most common pattern (8 of
24) consisted of organized, longitudinal layers of podoplanin-positive cells and vessels in the fibrotic zone (‘‘organized’’
pattern). 7 of 24 biopsies demonstrated a diffuse distribution of podoplanin-positive cells, accompanied by occasional,
dense clusters of podoplanin-positive cells. Five biopsies exhibited a mixed pattern, with some diffuse areas and some
organized areas ("mixed"). These contained cuboidal podoplanin-positive cells within SMA-negative epithelial structures
embedded in extracellular matrix. Less frequently observed was the complete absence of, or only focal accumulations of
podoplanin-positive fibroblasts outside of lymphatic vessels (podoplanin ‘‘low’’, 4 of 24 biopsies). Patients in this group
exhibited a lower index of systemic inflammation and a longer symptomatic period than in EPS patients with biopsies of the
"mixed" type (p,0.05). In summary we confirm the increased expression of podoplanin in EPS, and distinguish EPS biopsies
according to different podoplanin expression patterns which are associated with clinical parameters. Podoplanin might
serve as a useful adjunct to the morphological workup of peritoneal biopsies.
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Introduction
Encapsulating peritoneal sclerosis (EPS) is a rare, but life-
threatening complication of long-term PD [1,2,3]. Recent PD
registries described rates of 0.7–3.3%, an incidence of 4.9 per
1000 person-years, and a mortality of 42% one year post diagnosis
[4]. The diagnosis is based on the combination of clinical
symptoms (bowel obstruction), radiological findings (suggesting
extensive thickening of the peritoneal membrane as the cause of
bowel obstruction), and/or the histo-morphological picture [1].
Peritoneal thickening, bowel tethering, peritoneal calcification,
peritoneal enhancement and loculated fluid collections can be
visualized by computed tomography [1]. Peritoneal biopsy histo-
morphological features pathognomonic for EPS have not been
defined, and the importance of peritoneal biopsy in the clinical
diagnosis of EPS remains poorly established. Morphological signs
such as mesothelial denudation, extreme fibrotic thickening,
peritoneal fibroblast swelling, interstitial fibrosis, angiogenesis with
increased capillary density, and mononuclear cell infiltration are
all typical for EPS, but not specific [5,6,7]. Fibrin deposits may
lead to adhesions and permanent scarring, eventually resulting in
bowel obstruction.
Podoplanin, a member of a type-1 transmembrane sialomucin-
like glycoprotein family, serves as a marker of lymphatic
endothelial cells but is also expressed by mesothelial cells [8,9].
In a previous study we described podoplanin expression in 69
peritoneal biopsies including 18 patients with EPS. 15 of these
biopsies demonstrated a diffuse infiltration with podoplanin-
positive cells [10]. These cells were identified as SMA-positive
myofibroblasts, which did not express endothelial or other
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Figure 1. Podoplanin mRNA levels are increased in EPS. RNA samples from patients on PD without signs of EPS (n = 5), and with EPS (n = 5), as
well as control biopsies from patients with uremia (n = 5) and normal peritoneum taken during laparatomy (n = 5). The two groups were pooled as
"control" samples. Podoplanin mRNA levels were analyzed by real-time RT-PCR. The mean fold induction of podoplanin mRNA was normalized to
normal control samples.
doi:10.1371/journal.pone.0053382.g001
Table 1. Clinical information and laboratory values of patients from whom originated biopsy specimens studied by RT-PCR.
Variable
Uremic patients
(not on PD) PD EPS Normal biopsies
n= 5 5 5 5
Gender (male:female) 3:2 4:1 4:1 1:4
Age (years;mean 6SD) 54.4 (616.2) 64.4 (611.8) 51.6 (611.0) 56.2 (612.3)
PD-duration in months 35.2 (638.2), n.s. 72.6 (624.3)
Peritonitis 1:22 months 1:46 months
PDF: Neutral 4 2
Acidic 0 2
N.D. 1 1
Transporter status
High/high average 2 3
Low/low average 1 0
N.D. 1 2
Icodextrin 2/5 4/5
Diabetes 4/5 2/5 0/5 0/5
Smoker 2/5 1/5 2/5 0/5
Hypertension 3/5 3/5 5/5 2/5
Hb (g/dl 6 SD [13–18]) 10.7 (61.0) 12.2 (61.9) 9.7 (61.8) 12.4 (62.6)
Leukocytes (G/L 6 SD [4.0–11.3]) 8.5 (61.5) 6.4 (61.4) 6.7 (63.5) 5.4 (61.3)
CRP (mg/dl 6 SD [,0.1]) 1.1 (62.4) 1.9 (62.4) 6.4 (67.5) 0.1 (60.1)
Phosphate (mmol/l [0.68–1.68]) 1.7 (60.25) 1.3 (60.3) 1.2 (62.2)
Calcium (mmol/l [1.90–2.70]) 2.05 (60.12) 2.2 (60.1) 2.1 (60.3) 2.28 (60.1)
PTH (pmol/l [1.1–7.3]) 34.3 (66.8) 31.1 (626) 46 (649.4)
Urea-N (mg/dl [10–25]) 62.2 (622.9) 42.5 (622.2) 35.4 (614.2)
Creatinine (mg/dl [0.5–1.4]) 5.1 (60.94) 5.1 (62.3) 6.4 (62.9) 0.8 (60.14)
PD, peritoneal dialysis; EPS, encapsulating peritoneal sclerosis; n.s. not significant compared to EPS. PDF, peritoneal dialysis fluid; Hb, haemoglobin; PTH, parathyroid
hormone; CRP, C-reactive protein.
doi:10.1371/journal.pone.0053382.t001
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mesothelial markers [10]. This cell type was focally present in only
3 out of 16 specimens from PD patients without signs of EPS, and
in none of 35 controls [10]. The accumulation of podoplanin-
positive myofibroblasts in EPS was confirmed by Yaginuma and
colleagues using immunoelectron microscopy [11].
Here we confirm the prominent expression of podoplanin using
quantitative real-time RT-PCR, and describe four histological
patterns of podoplanin-positive cells in EPS biopsies which, we
propose, will facilitate morphologic diagnosis of EPS.
Results
Podoplanin mRNA Expression in Peritoneal Biopsies
To evaluate podoplanin expression on transcript level we
performed real-time RT-PCR on peritoneal biopsies (Table 1)
taken from uremic patients not on PD (n= 5), patients on PD
(n= 5), and from PD patients with clinical signs of EPS (n= 5). An
additional set of control biopsies were taken from normal
peritoneum during abdominal surgery (see material and methods).
Both control groups were pooled in this analysis (Figure 1). A
prominent and statistically significant induction of podoplanin
mRNA was demonstrated. Therefore the previously described
accumulation of podoplanin-positive myofibroblasts in EPS was
associated with significant induction of podoplanin mRNA
expression [10,11].
Podoplanin Patterns by Immunohistochemistry
The clinical and laboratory data of the 24 patients with EPS
included in the morphological analysis are presented in Table 2.
Podoplanin staining was first analyzed without knowledge of the
clinical information. This analysis led to segregation into four
groups of podoplanin patterns. Podoplanin-positive lymphatic
vessels were present in all four groups, whereas the groups differed
in the appearance of podoplanin-positive cells with the morphol-
ogy of myofibroblasts.
The most common pattern of podoplanin-positive cells was a
prominent staining of the superficial fibrotic layer, with longitu-
dinal alignment of podoplanin-positive cells and vessels (Figure 2
A). These longitudinal layers appeared well organized (Figure 2 A,
E) with podoplanin-positive cells and vessels arrayed in parallel
orientation (‘‘organized’’ pattern, 8 out 24 biopsies). The
corresponding distribution of SMA-positive cells was similar to
the pattern of podoplanin (Figure 2 B, D). In the podoplanin-
stained sections, prominent lymphatic vessels present in the
fibrotic layer (Figure 2 A, B arrowheads) were negative for SMA
expression on consecutive sections (Figure 2 D). In some fibrotic
zones the superficial layer contained fewer podoplanin- and SMA-
Table 2. Clinical information and laboratory values of patients with EPS.
Variable EPS
n= 24
Gender (male:female) 21/3
Age (years; mean ±SD) 55.1 (611.0)
PD-duration (months) 80 (635)
Peritonitis episodes 60 in 1919 months (1:32)
PDF
Neutral 9/24
Acidic 8/24
Both or N.D. 7/24
Transporter status 11
High/high average 5
Low/low average 8
N.D. last 6 months
Icodextrin 18/24
Diabetes 17/24
Smoker 9/24
Hypertension 22/24
Hb (g/dl, 13–18) 10.6 (62.9)
Leukocytes (G/L, 4.0–11.3) 8.7 (63.4)
Phosphate (mmol/l, 0.68–1.68) 1.3 (60.5)
Calcium (mmol/l, 1.9–2.7) 2.3 (60.3)
PTH (pmol/l, 1.1–7.3) 25.6 (625.1)
Urea-N (mg/dl, 10–25) 41.2 (615.6)
Creatinine (mg/dl, 0.5–1.4) 6.9 (62.2)
Time of onset of complaints to Surgery (months) 7.1 (65.5)
CRP (mg/dl, ,0.1) 9.0 (610.7)
Hb, haemoglobin; EPS, encapsulating peritoneal sclerosis; PD, peritoneal dialysis;
PDF, peritoneal dialysis fluid; PTH, parathyroid hormone; CRP, C-reactive protein; SD, standard deviation.
doi:10.1371/journal.pone.0053382.t002
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positive cells (Figure 2 F left upper corner, between arrowheads).
Podoplanin-positive lymphatic vessels were detectable in this
superficial layer (arrows in Figure 2 E).
The second most common appearance of podoplanin (7 out of
24 biopsies) was in a diffuse pattern with an irregular, random
distribution of podoplanin-positive cells (‘‘diffuse’’ pattern,
Figure 3). The cells seemed to be randomly distributed and
oriented within the fibrotic zones (Figure 3 A), in contrast to the
longitudinal orientation in the "organized" pattern (Figure 2 A).
Podoplanin-positive cells occupied a larger proportion of the visual
fields in biopsies of "diffuse" pattern (Figure 3 E). The individual
podoplanin-positive cells were embedded in extracellular matrix
(Figure 3 A). Other areas demonstrated dense accumulations of
podoplanin-positive cells with correspondingly less prominent
extracellular matrix (Figure 3 E). The SMA expression pattern was
very similar to the podoplanin staining (Figure 3 B, D, F), but
SMA-positive smooth muscle cells in vessel walls were podoplanin-
negative (Figure 3 C, D).
In 5 out of 24 biopsies areas of both ‘‘organized’’ (Figure 4 A, B)
and ‘‘diffuse’’ pattern (Figure 4 C, D) were observed, which we
referred to as ‘‘mixed’’ pattern. These biopsies demonstrated the
most variable appearance of podoplanin-positive cells. Interest-
ingly, these biopsies contained areas of cuboidal podoplanin-
positive cells, which were embedded in extracellular matrix
(Figure 4 E, F). Consecutive sections revealed that these cells
(arrowhead in 4 E) were SMA-negative (Figure 4 F). It is important
to note that this podoplanin-positive, SMA-negative cell type
differs in morphology (cuboidal rather than fibroblastic) and in
SMA expression from the majority of podoplanin-positive cells.
Clusters of podoplanin-positive, SMA-negative cuboidal cells were
completely surrounded by dense extracellular matrix. Some
podoplanin positive cells were separated from these structures.
Also these cells were completely surrounded by extracellular
matrix on consecutive sections a major part (but not all)
demonstrated expression of calretinin (indicating an mesothelial
origin/and or mesothelial differentiation, not illustrated).
In four out of 24 biopsies the expression of podoplanin was
mainly restricted to lymphatic endothelial cells (Figure 5). Partic-
ularly in the fibrotic zones, where a prominent accumulation of
podoplanin-positive cells was present in the biopsies with the other
Figure 2. Examples of the "organized" pattern of podoplanin in EPS. Peritoneal biopsies from patients with EPS were stained with
monoclonal antibodies against podoplanin (A, C, E). Consecutive section stained with monoclonal antibody against SMA (B, D, F) showed that many
cells appeared to express both proteins. In the fibrotic zone (between arrows in A) longitudinal layers of podoplanin-positive cells and vessels (A, C
arrowhead) are present, and on consecutive sections SMA-positive cells are detected. These ‘‘organized’’ longitudinal layers led to the description as
an "organized" pattern. The superficial layer illustrated in E (upper left corner) contains only some podoplanin-positive vessels, but few SMA-positive
cells. Below this superficial layer a prominent zone with podoplanin- and SMA-positive cells is present, as in panels A and B. Panels A-D are from a
single individual, panels E and F are from a different individual. (Original magnification, 200X in A, B, E, F; 630X in C, D.).
doi:10.1371/journal.pone.0053382.g002
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patterns, no podoplanin-positive myofibroblasts were detectable
(podoplanin ‘‘low’’ pattern. Figure 5 A, B). In some biopsies focal
accumulations of podoplanin-positive fibroblastic cells were
detected (Figure 5 C, D). In this histological class of biopsies,
location and detection of these scarce, focal areas of podoplanin-
positive cells may require analysis of several biopsy specimens from
one individual.
Importantly, patients with biopsies with the podoplanin ‘‘low’’
pattern had a significantly lower level of systemic inflammation (as
reflected by serum C-reactive protein concentrations, Figure 6 A),
but the longest time with symptoms (Figure 6 B). The groups did
not differ in mean age, time on PD, or number or frequency of
peritonitis episodes (Table 3). The number of CD20 positive B
cells, CD3 T cells and CD68 positive macrophages/DCs were
scored semi-quantitatively. Most biopsies demonstrated either a
mild (score 1) or severe (score 2) diffuse infiltration of CD3 and
more prominent CD68 positive cells. CD20 positive B cells were
rare within the fibrotic membranes. A single biopsy contained two
nodular accumulations on the abluminal side of the fibrotic
membrane. Larger accumualtions of infiltrating cells (score 3) were
rare. The mean scores of CD3 and CD68 positive infiltrating cells
in the biopsies were similarly distributed as the C-reactive protein,
with the highest scores in biopsies with a diffuse or mixed pattern
(Figure 6 C, D). B cells demonstrated low scores and no differences
between the groups.
Discussion
In a previous study we described a podoplanin-positive, SMA
positive cell population in 15 of 18 biopsies from patients with
EPS, whereas only focal accumulations of podoplanin-positive cells
were present in biopsies from 3 of 16 patients on PD without signs
of EPS [10]. We thus suggested that podoplanin staining might be
suitable as an adjunct to the morphological diagnosis of EPS. The
current study had two goals. The first was to examine podoplanin
expression in EPS with a different technique (i.e. mRNA
measurement by quantitative real-time RT-PCR). The second
goal was to further describe the pattern of podoplanin-positive
cells, particularly in those biopsies without the typical accumula-
tion of podoplanin-positive myofibroblasts.
Using quantitative real-time RT-PCR we were able to confirm
increased levels of podoplanin mRNA in peritoneal biopsies from
Figure 3. Examples of the "diffuse" pattern. Peritoneal biopsies from patients with EPS were stained with monoclonal antibodies against
podoplanin (A, C, E). Consecutive sections were stained with a monoclonal antibody against SMA (B, D, F). The diffusely distributed and randomly
oriented pattern of individual podoplanin-positive cells separated by matrix is illustrated in A, and at higher magnification in C. In E the same pattern
is illustrated with more densely distributed podoplanin-positive cells. At a higher magnification (C, D) the SMA-positive cells of arteries (arrow) were
podoplanin-negative, but the SMA-positive myofibroblasts (arrowhead) were podoplanin-positive. Panels A-D are from a single individual, panels E
and F are from a different individual. (Original magnification, 200X in A, B, E, F; 630X in C, D.).
doi:10.1371/journal.pone.0053382.g003
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patients with EPS on PD. Furthermore, a recent study confirmed
the existence of these podoplanin-positive fibroblastic cells by both
immunohistochemistry and by immunoelectron microscopy [11].
Thus, the first goal of the paper was achieved, as another
technique demonstrated increased podoplanin expression in a
different group of EPS patients.
The second part of the work aimed to extend the histological
description and pattern(s) of podoplanin-positive cells in peritoneal
biopsies. We found that the biopsies could be separated into four
morphological groups. From the diagnostic point of view, the
group with rare podoplanin-positive cells (‘‘podoplanin low’’) is an
important one, as this category might generate false negative
results for EPS. Four of 24 patients demonstrated podoplanin-
positive vessels (lymphatics), but only small and focal sites of
accumulation of podoplanin-positive cells. In our previous study,
the proportion of patients with this pattern was similar (with 3 of
16). Therefore, between 15 and 20% of biopsies from patients with
EPS exhibit a ‘‘low’’ podoplanin pattern. Patients with this
histological pattern had the lowest level of systemic inflammation
(as judged by serum levels of C-reactive protein), and the longest
history of symptoms. Therefore, this pattern could reflect a late
(and/or slowly progressive) disease state (fibrotic, or ‘‘burnt out’’).
It is important to note that these small clusters of podoplanin-
positive cells can usually be detected when sufficient material is
available and thoroughly examined, but these areas can easily be
missed on smaller biopsies.
Two additional, distinct patterns and a mixed pattern could be
identified. The "organized" pattern and the "diffuse" pattern were
observed with equal frequency, and were together most commonly
found. The "organized’ pattern was characterized by a longitu-
dinal organization of podoplanin-positive cells throughout the
fibrotic layer or the basal part of the fibrotic zone. In contrast, the
"diffuse" pattern was distinguished by a random accumulation of
podoplanin-positive cells across a larger area of biopsy. Five of 24
biopsies demonstrated a "mixed" pattern (with features of both
"organized" and "diffuse" patterns). The ‘‘mixed’’ pattern group
exhibited the highest level of inflammation and the shortest history
of symptoms prior to surgery. The "mixed" and the "diffuse" types
likely reflect the most active and aggressive phases of EPS, with
sites of very prominent podoplanin- and SMA-positive cell
accumulation. Furthermore the ‘‘mixed’’ and the ‘‘diffuse’’ type
demonstrated the strongest infiltration by T cells and CD68
positive macrophages/DCs.
Figure 4. Illustration of the ‘‘mixed’’ pattern. Peritoneal biopsies from patients with EPS were stained with monoclonal antibodies against
podoplanin (A, C, E). Consecutive sections were stained with monoclonal antibody against SMA (B, D, F). Examples of ‘‘organized’’ (A, B) and ‘‘diffuse’’
(C, D) patterns are illustrated from the same tissue specimen. An area of podoplanin-positive, cuboidal cells embedded in matrix is illustrated in E
(arrowhead), but these cells were SMA negative on consecutive sections (F). An SMA-positive myofibroblast is illustrated by the arrow (F, upper right).
Panels A-D are from a single individual, panels E and F are from a different individual. (Original magnification, 200X.).
doi:10.1371/journal.pone.0053382.g004
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The morphological patterns were not associated with the
number of peritonitis episodes and the groups did not differ in
age, time on PD, Icodextrin exposure, parathyroid hormon, and
calcium. Also not quite significant, patients with mixed pattern
demonstrated a trend towards higher leukocytes, lower urea and
lower phosphate (likely reflecting poorer nutritional status).
It is currently unclear whether the different morphological
podoplanin patterns are related to differences in the quantitative
podoplanin mRNA expression. Particularly, the podoplanin ‘‘low’’
pattern is likely associated with a decreased podoplanin mRNA
expression. Currently, the materials available for matched
podoplanin staining and mRNA quantification were not sufficient
to answer this question, but it will be evaluated in a future study.
The fibroblastic podoplanin- and SMA-positive cell type typical
for EPS was found to be negative for calretinin (a marker of
mesothelial cells [10]. Podoplanin positive stromal cells (called
lymphoid stromal cells,) have been described as follicular reticular
cells (also positive for SMA) in T cell zones of secondary lymphatic
organs, in thymic medulla, in intestinal lamina propria, and in
tertiary lymphoid organs formed during chronic infiltration
[17,18,19]. During development of secondary lymphoid organs
the lymphoid tissue inducer cells activate podoplanin positive
stromal cells via lymphotoxin to release chemokines and
upregulate adhesion molecules [18]. Some forms of Inflammation
recapitulate the formation of lymphoid stromal cells as the
accumulation of podoplanin positive stromal cells was demon-
strated in different inflammatory models in the mouse (e.g. models
of autoimmunity, inflammation of mouse ears induced by
adjuvant) [18]. During inflammation the lymphoid stromal cells
resulted from local proliferation of non-epithelial precursor cells
[18]. The development of these cells seems to be dependent on the
injury process. Studies in chronically inflamed kidneys did not
demonstrate the accumulation of podoplanin positive myofibro-
blasts, whereas SMA positive cells form a prominent part of the
interstitial fibroblasts in chronic renal injury [16]. Furthermore, in
patients on PD with simple peritoneal fibrosis, diffuse accumula-
tion of podoplanin positive myofibroblasts was rarely detected.
Therefore the podoplanin positive cells in EPS reflect features of
lymphoid stromal cells. As nodular infiltrates were rarely present
full tertiary lymphoid organs were not present, these cells do not
seem to promote the formation of lymphoid tissue in the EPS
membranes. Future studies will need to further describe these cells
with other markers of lymphoid stromal cells. The question
remains whether these cells are the consequence of the injury
process of EPS or a driving force.
Another podoplanin positive cell type has been described in
mice. During zymosan peritonitis a F4/80 positive cell expressing
podoplanin has been described and called fibroblastic macro-
phages [20]. In our study the overall pattern of CD68 (a marker of
human monocyte/macrophages/DCs) did not match the podo-
planin staining, but further studies using double labelling need to
evaluate whether similar fibroblastic macrophages are present in
human EPS.
In the biopsies with a ‘‘mixed’’ pattern clusters of podoplanin-
positive cuboidal cells were found embedded in extracellular-
matrix (illustrated in Figure 4E). As these cells cells were SMA
negative, these might reflect mesothelial cells [21]. In parallel
staining for calretinin (as a marker of mesothelial cells) a major
part of these cells demonstrated calretinin expression, but a smaller
part did not. Therefore these cells do not seem to be typical
mesothelial cells but the differentiation of these cells need further
description. In Figure 4C the excess of podoplanin-positive cells
over SMA-positive cells (in Figure 4 D) may reflect the presence of
this cell type. These areas might reflect sites of early epithelial-to-
mesenchymal cell transition or a cell on the way towards a
mesothelial phenotype.
Figure 5. Example of the podoplanin ‘‘low’’ pattern. A peritoneal biopsy from an EPS patient was stained with monoclonal antibodies against
podoplanin (A, C), and consecutive sections were stained with a monoclonal antibody against SMA (B, D, orig. X200). Panel A illustrates an area in
which the fibrotic zone does not demonstrate a significant accumulation of podoplanin-positive cells (the arrowhead show some positive small
vessels). In small areas of the biopsy the typical presence of podoplanin-positive myofibroblast was detectable The arrowhead in B marks a
podoplanin-positive lymphatic vessel, not stained by SMA on the consecutive section (D).
doi:10.1371/journal.pone.0053382.g005
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The question remains whether the patterns illustrated reflect a
continuum (likely from "mixed/diffuse" pattern via "organized"
towards "low" pattern) or different disease entities. The clinical
data suggest that the "mixed/diffuse" pattern reflects earlier
(active) phases, whereas the "organized" and, particularly, the
podoplanin ‘‘low’’ pattern are rather later stages. If true, then the
‘‘low’’ pattern might not be susceptible to anti-inflammatory
treatment, a hypothesis that could be tested. This novel
stratification of EPS patients into groups exhibiting distinct
podoplanin expression patterns could be of significant diagnostic
and prognostic impact, if it can be confirmed in other EPS biopsy
registries.
Methods
All peritoneal biopsies were obtained from the peritoneal biopsy
registry at the Robert-Bosch-Hospital, Stuttgart, Germany. The
human peritoneal tissue, blood and peritoneal dialysate for
research purposes were collected after written consent of the
patient was given. The study was approved by the local ethics
committee (#322/2009BO1, Eberhard-Karls University Tuebin-
gen, Germany).
Additionally, shortly after tissue excision, 20 samples from
patients on PD without EPS (n= 5), patients with EPS (n = 5),
uremic patients not on PD (n= 5), and normal tissue taken during
cholecystectomy (n = 3), hemicolectomy (n= 1) and closure of
loop-colostomy (n= 1), all without signs of systemic and local
inflammation, were washed in 0.9% saline solution, placed in
RNAlater (Qiagen, Hilden, Germany), then stored at 280uC for
subsequent RNA extraction.
Clinical data collection included demographic data, cause of
primary renal disease, comorbidities (diabetes, hypertension and
smoking status), PD details and the date of dialysis initiation. Body
mass index, peritonitis rate, medications. and time of onset of
symptoms were also recorded. The diagnosis of EPS was made
according to the clinical criteria of Nakamoto et al. [12], the
radiological criteria of Vlijm et al. [13] and the histological criteria
of Honda et al. [5]. Biopsies of the parietal peritoneum were
taken, formalin-fixed and embedded in paraffin following routine
protocols. All patients were on hemodialysis after surgery.
Quantitative Real-time RT-PCR
RNA was isolated from tissues frozen and immersed in
RNAlater (Qiagen), using the miRNeasy Mini-Kit (Qiagen)
according to the description of the manufacturer. 50–100 mg
tissue samples were incubated in 0.7 ml Qiazol reagent and
homogenized using a rotor-stator homogenizer (Ultra-Turrax T8,
IKA-Werke Staufen, Germany) for 1 minute. The homogenate
was extracted with 0.14 ml chloroform, and phase separation of
the solution was achieved by centrifugation. The clear, aqueous
supernatant containing total RNA was removed, and total RNA
was twice precipitated with 75% ethanol, and re-suspended in
nuclease-free water.
Figure 6. Association between podoplanin pattern and clinical parameters and morphological scores of inflammatory cells.
Illustrated are the mean C reactive protein (CRP) levels (A), the mean duration of symptoms (in months, B), the mean scores for CD3 positive T cells (C)
and the mean scores for CD68 positive cells (D) for the four histological groups of podoplanin patterns. The infiltrating cells were scored semi-
quantitatively as described in materials and methods.
doi:10.1371/journal.pone.0053382.g006
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RNA was measured using a NanoDrop Spectrophotometer
2000c (Peqlab Biotechnologie GmbH, Erlangen, Germany). RNA
integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). First-strand cDNA was synthe-
sized with TaqMan RT reagents (Applied Biosystems, Darmstadt,
Germany). Pre-developed TaqMan reagents were used for human
podoplanin and housekeeping genes GAPDH and 18SrRNA
(Applied Biosystems, Darmstadt, Germany). The mRNA expres-
sion was analyzed by the delta delta Ct method as previously
described [14].
Immunohistochemistry
Immunohistochemistry was performed as previously described
[10,15]. In brief, paraffin-embedded tissue sections were depar-
affinized in xylene, rehydrated in a graded series of ethanols, and
incubated in 3% hydrogen peroxide (to block endogenous
peroxidases). Antigen retrieval was performed in an autoclave
oven, using antigen retrieval solution (Vector, Burlingame, CA).
The primary antibodies were applied for 1 hour. Incubation with
biotinylated secondary reagents (Vector) was performed for 30
minutes, followed by washing, then exposure to ABC reagent
(Vector). 3939diaminobenzidine (DAB, Sigma, Taufkirchen, Ger-
many) with metal enhancement (resulting in a black colour
product) was used as a detection system. Nuclei were counter-
stained with methyl green.
A monoclonal mouse anti-human podoplanin antibody (D2–40,
Signet Laboratories, Dedham, MA) was used on all biopsies
[15,16]. As control tissues we used sections of human renal
allograft nephrectomies, including the replacement of the primary
antibody by isotype-matched control immunoglobulins (Figure
S1). These controls did not demonstrate positive staining (Figure
S1 B). For detection of SMA a monoclonal mouse antibody was
used (1A4, DakoCytomation, Glostrup, Denmark), which stains
smooth muscle cells in arterial walls and in myofibroblasts (Figure
S1 C, D). Additional sections were stained with a monoclonal
antibody against CD68 (Clone PG-M1, DAKO Germany,
Hamburg), with a monoclonal antibody against CD3 (clone:
CD3–12, rat anti-human, Serotec, Oxford, UK), and with a
monoclonal antibody against CD20 (clone L26; DakoCytomation,
Dako Deutschland, Hamburg, Germany) [16]. Selected biopsies
were stained with calretinin (Dak Calret 1, DakoCytomation,
Glostrup, Denmark) a marker of mesothelial cells. The extent of
inflammatory infiltrates were semi-quantitatively scored from 0 (no
or scattered cells), 1 (milde diffuse infiltrates), 2 (severe diffuse
infiltrates) to 3 (severe diffuse infiltrates with larger cell accumu-
lations) by an observer blinded to the morphological podoplanin
pattern and the clinical information.
Statistical Analysis
Statistical analysis was performed using InStatH software
(Version 3.05, Intuitive Software for Science, San Diego, CA).
For comparison of means, the non-parametric Kruskal-Wallis test
and Dunn’s multiple comparisons test were applied. A p,0.05 was
Table 3. Clinical information and laboratory values according to the morphological pattern of podoplanin.
Diffuse Mixed Organised Low
n= 7 5 8 4
Gender (male:female) 7/0 4/1 7/1 4/0
Age (years;mean ±SD) 51.7 (615.9) 46.4 (67.3) 55.5 (612.2) 47.3 (617.2)
PD-duration in months 71 (637) 99 (633) 86 (629) 59 (639)
Peritonitis 1:26 1:37 1:33 1:26
PDF
Neutral 3 1 4 1
Acidic 2 1 3 2
Both or N.D. 2 3 1 1
Transporter status
High/high average 2 3 5 1
Low/low average 1 1 1 2
N.D. 4 1 2 1
Icodextrin 4 5 6 3
Diabetes 2 1 2 1
Smoker 3 2 2 2
Hypertension 6 4 8 4
Hb (g/dl ± SD [13–18]) 84 (631.1) 115 (629.3) 116 (621.0) 113 (626.4)
Leukocytes (G/L ±SD [4.0–11.3]) 8.4 (62.3) 11.2 (65.2) 8.6 (63) 6.5 (62.2)
Phosphate (mmol/l [0.68–1.68]) 1.7 (60.6) 1.0 (60.5) 1.3 (60.5) 1.4 (60.6)
Calcium (mmol/l [1.90–2.70]) 2.1 (60.2) 2.3 (60.3) 2.4 (60.3) 2.3 (60.4)
PTH (pmol/l [1.1–7.3]) 28.5 (617.6) 12.9 (68.8) 21 (630.5) 43 (630.8)
Urea-N (mg/dl [10–25]) 92.1 (632) 69.8 (627.5) 87.4 (627.8) 105.8 (652.3)
Creatinine (mg/dl [0.5–1.4]) 6.8 (62.4) 6.8 (62.1) 7 (62.2) 6.7 (63.1)
PD, peritoneal dialysis; EPS, encapsulating peritoneal sclerosis; PDF, peritoneal dialysis fluid; Hb, haemoglobin; PTH, parathyroid hormone.
doi:10.1371/journal.pone.0053382.t003
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considered to be significant. Error bars demonstrate standard
error of the mean (SEM).
Conclusions
The current study confirms elevated podoplanin expression in
EPS peritoneal biopsies. The morphological evaluation of
podoplanin can separate histological groups with different clinical
features, and in the future might guide both diagnosis and
treatment of EPS. The similarity of these podoplanin positive cells
with lymphoid stromal cells needs further evaluation.
Supporting Information
Figure S1 Illustration of podoplanin and SMA in control
tissue. Immunohistochemistry was performed on tissue sections
from an allograft nephrectomy (A, C), with monoclonal antibodies
against podoplanin (A) and smooth muscle actin (C). Consecutive
sections of the renal allograft were stained with the isotype
immunoglobulin control (as negative control B, D). Note the
staining of periarterial lymphatic vessels (arrowhead in A) and the
absence of staining in B. Panel C shows SMA-positive cells in the
walls of an artery (arrowhead) and an arteriole (arrow). No staining
is present in the isotype immunoglobulin control (D). (Original
magnification, 200X)
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